TSX Penny Stocks To Consider In October 2024

In This Article:

The Canadian market has seen a notable upswing, with a 1.0% increase over the last week and an impressive 27% rise in the past year, alongside forecasts of annual earnings growth at 16%. In light of these conditions, identifying stocks with strong fundamentals becomes crucial for investors seeking potential growth opportunities. Penny stocks may be considered a dated term, but they continue to represent viable investment options by offering access to smaller or newer companies that could capitalize on current market momentum.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

PetroTal (TSX:TAL)

CA$0.68

CA$620.88M

★★★★★★

Findev (TSXV:FDI)

CA$0.41

CA$11.75M

★★★★★☆

Winshear Gold (TSXV:WINS)

CA$0.165

CA$4.4M

★★★★★★

Mandalay Resources (TSX:MND)

CA$3.24

CA$297.04M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.29

CA$119.71M

★★★★★★

Amerigo Resources (TSX:ARG)

CA$1.80

CA$303.41M

★★★★★☆

Foraco International (TSX:FAR)

CA$2.40

CA$221.84M

★★★★★☆

East West Petroleum (TSXV:EW)

CA$0.035

CA$3.17M

★★★★★★

Newport Exploration (TSXV:NWX)

CA$0.115

CA$12.14M

★★★★★★

NamSys (TSXV:CTZ)

CA$1.11

CA$30.89M

★★★★★★

Click here to see the full list of 947 stocks from our TSX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

PharmaTher Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on developing and commercializing pharmaceuticals with novel delivery methods to improve patient outcomes, with a market cap of CA$25.67 million.

Operations: PharmaTher Holdings Ltd. has not reported any distinct revenue segments.

Market Cap: CA$25.67M

PharmaTher Holdings Ltd., with a market cap of CA$25.67 million, is pre-revenue and debt-free, though it faces financial constraints with less than a year of cash runway. The company reported a reduced net loss of CA$3.12 million for the year ended May 31, 2024, down from CA$6.42 million the previous year. Its strategic focus on ketamine development is underscored by an ongoing FDA review for its New Drug Application, targeting Parkinson's Disease and addressing U.S. ketamine shortages. Despite high volatility in share price and negative return on equity, no significant shareholder dilution occurred recently.

CNSX:PHRM Debt to Equity History and Analysis as at Oct 2024
CNSX:PHRM Debt to Equity History and Analysis as at Oct 2024

Arizona Gold & Silver

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Arizona Gold & Silver Inc. is involved in acquiring and exploring mineral properties in the United States, with a market cap of CA$35.51 million.